Vlad Prelipcean, MD
Internal Medicine · Pinson, ALNPI 1033188966
Payments from drug & device makers
Across 426 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$857
- AstraZeneca$744
- Boehringer Ingelheim$657
- Amgen$578
- Pfizer$566
- Johnson & Johnson$518
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,151100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $857 |
| AstraZeneca | 35 | $744 |
| Boehringer Ingelheim | 36 | $657 |
| Amgen | 37 | $578 |
| Pfizer | 36 | $566 |
| Johnson & Johnson | 34 | $518 |
| AbbVie(2 entities) | 30 | $408 |
| GSK | 20 | $344 |
| Lilly USA, LLC | 16 | $267 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $257 |
| Exact Sciences | 15 | $257 |
| Amarin Pharma, Inc. | 17 | $249 |
| Bayer | 13 | $214 |
| Sanofi-aventis U.S. LLC | 7 | $131 |
| Abbott | 1 | $126 |
| Astellas Pharma US Inc | 6 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $103 |
| Merck | 6 | $103 |
| Esperion Therapeutics, Inc. | 4 | $70 |
| Dexcom, Inc. | 4 | $67 |
| Novartis | 3 | $60 |
| Antares Pharma, Inc. | 3 | $58 |
| Avanir Pharmaceuticals, Inc. | 3 | $50 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 3 | $47 |
| Biogen | 2 | $43 |
| Shield Therapeutics Inc | 2 | $37 |
| Arbor Pharmaceuticals, Inc. | 2 | $35 |
| Eisai Inc. | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Genentech USA, Inc. | 1 | $22 |
| Boston Scientific | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Emmaus Medical, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre$126
- FARXIGA$125
- JARDIANCE$122
How this compares
$7,151 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 293 | $228,863 |
| OzempicSemaglutide | 179 | $215,072 |
| TrulicityDulaglutide | 122 | $152,536 |
| JanuviaSitagliptin Phosphate | 67 | $67,645 |
| FarxigaDapagliflozin Propanediol | 55 | $64,590 |
| MounjaroTirzepatide | 52 | $60,347 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $59,263 |
| JardianceEmpagliflozin | 54 | $58,743 |
| RybelsusSemaglutide | 22 | $50,468 |
| XareltoRivaroxaban | 47 | $36,393 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 38 | $29,839 |
| JanumetSitagliptin Phos/Metformin Hcl | 28 | $27,400 |
| MyrbetriqMirabegron | 42 | $27,357 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $25,730 |
| ProliaDenosumab | 12 | $21,791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $857 | $265,540201 claims |
| PfizerEliquis | $566 | $228,863293 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $267 | $212,883174 claims |
| MerckJanuvia, Janumet, Janumet Xr | $103 | $102,227106 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $744 | $80,93281 claims |
| GSKTrelegy Ellipta | $344 | $59,26391 claims |
| Boehringer IngelheimJardiance | $657 | $58,74354 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $115 | $38,47263 claims |
| Johnson & JohnsonXarelto | $518 | $36,39347 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $131 | $29,83938 claims |
| AmgenProlia | $578 | $21,79112 claims |
| AbbVieSynthroid | $408 | $5,14748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Pinson
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.